Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial [Phase 2]
The PROTECT CLL trial is a Phase 2 study evaluating vaccination with PCV20 and PPSV23 in patients with CLL-associated immunodeficiency; the …
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients [NA]
This study examines how structured exercise affects immune phenotype in patients with indolent non-Hodgkin lymphoma and chronic lymphocytic …
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL [Phase 3]
A Phase 3 clinical trial is planned to compare NX-5948 against Pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia and small l…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies [Phase 1]
Phase 1 study evaluating armored CD19-targeted CAR T cells in patients with relapsed or refractory chronic lymphocytic leukemia; status is a…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL [Phase 2]
This update covers a Phase 2 trial evaluating shortening treatment duration with acalabrutinib in combination with obinutuzumab for chronic …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) [Phase 2]
A Phase 2 trial evaluating the Bruton's tyrosine kinase degrader BGB-16673 in combination with the BCL-2 inhibitor Sonrotoclax for treatment…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) [Phase 3]
This clinical trial update describes Surovatamig as consolidation therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma wit…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study evaluating safety, efficacy, and pharmacokinetics of mosunetuzumab alone and in combination with venetoclax for relapsed or re…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
A recruiting study evaluating predictors of health-related quality of life in adults with chronic lymphocytic leukemia or small lymphocytic …
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Survivors Uniting for Remote Guided Exercise [NA]
Clinical trial update from Colorado State University about a remote guided exercise program for cancer survivors; the study is currently rec…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
Clinical trial evaluating hematopoiesis in patients with Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia compared with heal…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) [Phase 1, Phase 2]
A Phase 1/2 clinical trial of SENTRY-CD19, a CD19-targeted gene therapy, in multiple CD19-positive hematologic malignancies is currently rec…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies [Phase 2]
This Phase 2 clinical trial update describes evaluating emavusertib in combination with an approved Bruton tyrosine kinase inhibitor for chr…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) [Phase 3]
This clinical trial update notes a Phase 3 study evaluating DZD8586 versus investigator's choice in relapsed/refractory chronic lymphocytic …
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant [Phase 1]
Phase 1 clinical trial evaluating CMV-MVA Triplex Vaccine to enhance CMV-specific immunity and prevent CMV viremia in patients undergoing ha…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL [Phase 2]
Phase 2 clinical trial update for APG-2575 in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; the study is …
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL [Phase 1, Phase 2]
This clinical trials update describes a phase 1/2 study of a CD19 CAR T-cell therapy with CD34 selection for patients with CD19-positive rel…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies [Phase 1]
Phase 1 clinical trial evaluating Sonrotoclax (BGB-11417), a Bcl-2 inhibitor, in participants with mature B-cell malignancies. The study is …
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) [Phase 2]
A Phase II clinical trial is investigating a triplet regimen of zanubrutinib, obinutuzumab, and venetoclax in patients with chronic lymphocy…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating a three-drug combination (acalabrutinib, venetoclax, and durvalumab) for Richter transformation arising …
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype [Phase 2]
Phase 2 study evaluating nemtabrutinib combined with pembrolizumab for Richter transformation and Diffuse Large B-Cell Lymphoma in patients …
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania
A real-world study in Romania evaluates outcomes for Chronic Lymphocytic Leukemia patients treated with acalabrutinib. The study is sponsore…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors
This clinical trial update reviews hypertension and arrhythmia events in patients with chronic lymphocytic leukemia treated with BTK inhibit…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLL [NA]
This entry describes an ongoing clinical nutrition trial (CLL-IMPACT) investigating immune and metabolic changes in early-stage chronic lymp…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
Phase 1 study evaluating NX-2127 in adults with relapsed or refractory B-cell malignancies; currently recruiting.